Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:depression
|
| gptkbp:administered_by |
intramuscular injection
|
| gptkbp:approves |
gptkb:2010
gptkb:U._S._Food_and_Drug_Administration |
| gptkbp:available_on |
generic medication
|
| gptkbp:chemical_formula |
C27 H36 N4 O4 S
|
| gptkbp:clinical_trial |
ongoing research
|
| gptkbp:contraindication |
severe renal impairment
severe liver impairment hypersensitivity to paliperidone |
| gptkbp:developed_by |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:dosage_form |
suspension
|
| gptkbp:duration |
monthly injection
|
| gptkbp:formulation |
long-acting injectable
|
| https://www.w3.org/2000/01/rdf-schema#label |
paliperidone palmitate
|
| gptkbp:incompatibilities |
do not mix with other medications
|
| gptkbp:indication |
schizophrenia
|
| gptkbp:ingredients |
gptkb:paliperidone
|
| gptkbp:interacts_with |
antidepressants
antihypertensives anticonvulsants CYP3 A4 inducers CYP2 D6 inhibitors |
| gptkbp:is_monitored_by |
gptkb:weight
blood glucose lipid levels |
| gptkbp:lifespan |
approximately 30 days
|
| gptkbp:marketed_as |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:metabolism |
liver
|
| gptkbp:patient_education |
potential side effects
importance of adherence need for regular follow-up |
| gptkbp:pharmacokinetics |
highly protein-bound
dopamine D2 receptor antagonist oral bioavailability is low serotonin 5-HT2 A receptor antagonist |
| gptkbp:related_to |
gptkb:risperidone
|
| gptkbp:route_of_administration |
intramuscular
|
| gptkbp:side_effect |
drowsiness
weight gain increased cholesterol hyperglycemia extrapyramidal symptoms |
| gptkbp:storage |
refrigerated
|
| gptkbp:symptoms |
anxiety
nausea vomiting irritability insomnia |
| gptkbp:trade |
gptkb:Invega_Sustenna
|
| gptkbp:type_of_care |
improved with long-acting formulation
|
| gptkbp:used_for |
treatment of schizophrenia
|
| gptkbp:bfsParent |
gptkb:Invega_Trinza
|
| gptkbp:bfsLayer |
7
|